Emerald Acquisition’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

Emerald Acquisition’s Portfolio CBMG Stock Details CBMG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	$28K	Buy	+1,941	New	+$27.6K	﹤0.01%	2928

Other funds holding CBMG

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BIM

BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Zurich Cantonal Bank Zurich, Switzerland $46B AUM 27.59% 1-Year Est. Return

Emerald Acquisition's CBMG Position: Q3 2016 in Review

Emerald Acquisition opened a new position in Cellular Biomedicine Group, Inc. (CBMG) in Q3 2016: 1,941 shares worth $28K. The stake represents ﹤0.01% of the portfolio and ranks #2928 among its holdings.

36 funds tracked by Wall St. Rank hold CBMG as of Q3 2016.

Emerald Acquisition held 1,941 shares of Cellular Biomedicine Group, Inc. worth $28K as of Q3 2016.
Cellular Biomedicine Group, Inc. was a new Emerald Acquisition position in Q3 2016.
Cellular Biomedicine Group, Inc. made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #2928 holding.
36 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.